Drop the extra switching studies for interchangeable oncology biosimilars
US law lets a pharmacist swap an 'interchangeable' biosimilar without asking the prescriber, but earning that label used to need costly switching studies; the FDA now says those are usually unnecessary, which should be made permanent for cancer antibodies.
Overview
Interchangeability is a US-only regulatory status that allows pharmacy-level substitution. Historically it required dedicated switching studies, which delayed and added cost to biosimilar programmes. In 2024 the FDA issued draft guidance stating that switching studies are generally not needed to demonstrate interchangeability. Finalising that position and applying it to the oncology antibodies would remove a barrier to automatic substitution in the 40-plus states whose pharmacy laws recognise the status.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Regulatory divergence between regions · Regulatory divergence means a drug approved in one country can take years to reach another, or never arrive.
Pages like this
not linked directly; found by shared links- CompanyIntas Pharmaceuticals (Accord Healthcare)
Shares Biosimilar, Prices and value.
- IdeaOne evidence plan agreed by regulator and payer before the pivotal trial
Shares Regulatory divergence between regions, Prices and value.
- InstitutionComisión Federal para la Protección contra Riesgos Sanitarios
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- IdeaFederal oral chemotherapy parity for self-funded employer plans
Shares Regulatory divergence between regions, Prices and value.
- IdeaPay a flat fee for giving a Part B drug instead of 6% of its price
Shares Biosimilar, Prices and value.
- InstitutionACCELERATE
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- InstitutionSwissmedic
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- IdeaProvisional prices for surrogate-endpoint approvals, reset when survival data arrive
Shares Regulatory divergence between regions, Prices and value.